← Back to Screener
INmune Bio Inc. Common stock (INMB)
Price$1.49
Favorite Metrics
Price vs S&P 500 (26W)-30.79%
Price vs S&P 500 (4W)14.44%
Market Capitalization$38.55M
All Metrics
Book Value / Share (Quarterly)$0.88
P/TBV (Annual)1.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-48.68%
Cash Flow / Share (Quarterly)$-0.89
Price vs S&P 500 (YTD)-11.19%
Net Profit Margin (TTM)-19478.00%
EPS (TTM)$-1.92
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-1.92
Revenue Growth (5Y)37.97%
EPS (Annual)$-1.86
ROI (Annual)-195.26%
Net Profit Margin (5Y Avg)-87209.13%
Cash / Share (Quarterly)$0.93
ROA (Last FY)-141.98%
Revenue Growth TTM (YoY)257.14%
EBITD / Share (TTM)$-1.85
ROE (5Y Avg)-97.66%
Operating Margin (TTM)-19810.00%
Cash Flow / Share (Annual)$-0.89
P/B Ratio1.64x
P/B Ratio (Quarterly)1.76x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)275.95x
Net Interest Coverage (TTM)-52.34x
ROA (TTM)-130.13%
EPS Incl Extra (Annual)$-1.86
Current Ratio (Annual)3.55x
Quick Ratio (Quarterly)3.48x
3-Month Avg Trading Volume0.43M
52-Week Price Return-80.16%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.88
P/S Ratio (Annual)770.97x
Asset Turnover (Annual)0.00x
52-Week High$11.64
Operating Margin (5Y Avg)-88339.48%
EPS Excl Extra (Annual)$-1.86
Tangible BV CAGR (5Y)1.12%
26-Week Price Return-22.04%
Quick Ratio (Annual)3.48x
13-Week Price Return-5.84%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.55x
Enterprise Value$13.798
Revenue / Share Growth (5Y)20.11%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-21.00%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-91866.00%
Cash / Share (Annual)$0.93
3-Month Return Std Dev73.53%
Net Income / Employee (TTM)$-2
ROE (Last FY)-195.26%
Net Interest Coverage (Annual)-52.22x
EPS Basic Excl Extra (Annual)$-1.86
Receivables Turnover (TTM)0.07x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.92
Receivables Turnover (Annual)0.05x
ROI (TTM)-171.01%
P/S Ratio (TTM)770.97x
Pretax Margin (5Y Avg)-87209.13%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.88
Price vs S&P 500 (52W)-115.26%
Year-to-Date Return-7.05%
5-Day Price Return16.94%
EPS Normalized (Annual)$-1.86
ROA (5Y Avg)-72.94%
Net Profit Margin (Annual)-91866.00%
Month-to-Date Return28.32%
EBITD / Share (Annual)$-1.85
Operating Margin (Annual)-94766.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-91.47%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.92
P/TBV (Quarterly)1.76x
P/B Ratio (Annual)1.76x
Pretax Margin (TTM)-19478.00%
Book Value / Share (Annual)$0.88
Price vs S&P 500 (13W)-8.71%
Beta1.06x
Revenue / Share (TTM)$0.00
ROE (TTM)-171.01%
52-Week Low$1.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.10
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INMBINmune Bio Inc. Common stock | 770.97x | 257.14% | — | — | $1.49 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
INmune Bio is a clinical-stage biotechnology company developing immunotherapies designed to reprogram patients' innate immune systems to combat cancer. The company's pipeline includes multiple candidates across oncology and other therapeutic areas, positioned to address significant unmet medical needs in immuno-oncology.